Current Opinion in Oncology最新文献_第10页

Sarcoma incidence worldwide: regional differences in histology and molecular subtypes. 全球肉瘤发病率：组织学和分子亚型的地区差异。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-25 DOI: 10.1097/CCO.0000000000001046

Ming-Jing Lee, Tom Wei-Wu Chen

{"title":"Sarcoma incidence worldwide: regional differences in histology and molecular subtypes.","authors":"Ming-Jing Lee, Tom Wei-Wu Chen","doi":"10.1097/CCO.0000000000001046","DOIUrl":"10.1097/CCO.0000000000001046","url":null,"abstract":"Purpose of review: There are numerous sarcoma subtypes and vary widely in terms of epidemiology, clinical characteristics, genetic profiles, and pathophysiology. They also differ widely between ethnic groups. This review focuses on the different incidence rates of sarcomas in different regions and the potential explanations for these disparities.Recent findings: In an intercontinental study using national cancer registry databases from France and Taiwan, the French population had a higher risk of liposarcomas, leiomyosarcomas, and synovial sarcomas, whereas the Taiwanese population had a higher incidence of angiosarcomas and malignant peripheral nerve sheath tumors. The anatomical distribution of these sarcomas also varied between these two regions. In France, most angiosarcoma cases occurred in the extremities and trunk, whereas in Taiwan, angiosarcoma cases in the abdomen and pelvis were more common. Another international study showed that in addition to the common known TP53 and NF1 germline mutations, genes involved in centromere and telomere maintenance were also involved in sarcomagenesis. We reviewed factors related to genetics, environmental effects, chemical exposure, and radiation exposure that could explain the differences in sarcoma incidence among different geographical or ethnic regions.Summary: Our understanding of the potential cause of sarcomas with different subtypes is limited. Establishing a comprehensive global database for patients with sarcomas from all ethnic groups is essential to deepen our understanding of the potential risk factors and the pathophysiology of all sarcoma subtypes.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"276-281"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials. 旨在提高肿瘤科预先护理计划采用率的干预措施：近期随机对照试验的范围界定综述。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-09 DOI: 10.1097/CCO.0000000000001045

Yves Libert, Caroline Langhendries, Lisa Choucroun, Isabelle Merckaert

{"title":"Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials.","authors":"Yves Libert, Caroline Langhendries, Lisa Choucroun, Isabelle Merckaert","doi":"10.1097/CCO.0000000000001045","DOIUrl":"10.1097/CCO.0000000000001045","url":null,"abstract":"Purpose of review: The evidence regarding the effectiveness of interventions aiming to improve ACP uptake appears mixed. The purpose of this scoping review is to summarize findings from recent RCTs assessing the efficacy of interventions designed to increase ACP uptake in cancer care.Recent findings: The PubMed database was searched for studies published between 2021 and 2023. Ten RCTs were identified that evaluated a wide range of interventions aimed at encouraging or facilitating ACP communication among patients with advanced cancer, caregivers, and HCPs. Three RCTs developed ACP facilitation tools for patients and sometimes caregivers. Six RCTs involved integrating trained ACP facilitators into patient care, and one RCT used nudges to encourage oncologists trained in ACP discussions to initiate discussions with patients at highest risk of short-term mortality. Most of the reviewed interventions were based on previously tested intervention approaches or tools.Summary: The key effects identified in this review are the facilitation of ACP discussions among patients, caregivers, and HCPs, and the documentation of patient preferences in the medical record. The direct involvement of facilitators in ACP document drafting and inclusion in patient files, as well as interventions prompting end-of-life discussions, contributed to this effect.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"233-247"},"PeriodicalIF":2.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11155288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140916255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors. 综合肿瘤学模式在处理青少年和年轻成人（AYA）癌症患者和幸存者的不良反应和生存问题方面的现有证据。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-02-26 DOI: 10.1097/CCO.0000000000001033

Rukh Yusuf, Ding Quan Ng, Lilibeth Torno, Alexandre Chan

{"title":"Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors.","authors":"Rukh Yusuf, Ding Quan Ng, Lilibeth Torno, Alexandre Chan","doi":"10.1097/CCO.0000000000001033","DOIUrl":"10.1097/CCO.0000000000001033","url":null,"abstract":"Purpose of review: Symptom burden of cancer diagnosis and treatment has led adolescents and young adult cancer patients (AYAC) and survivors to seek different self-management strategies including integrative oncology (IO) modalities. IO holds great promise to improve survivorship issues in adolescents and young adult (AYA) cancer survivors. This review aims to encompass the current evidence of IO modalities and to analyze the efficacy of IO for managing survivorship issues among AYA cancer patients and survivors.Recent findings: Nineteen randomized controlled trials included in this review evaluated mind and body modalities including both physical and psychological (74%) and psychological only (26%) modalities. Most assessed IO modalities were physical activity (PA) (37%) and structured exercise (10%). Most effective IO modalities found were PA, massage, mindfulness-based stress reduction (MBSR) and light therapy for treating AYA symptom burden. The Cochrane risk of bias (RoB-2) concluded 21% studies had high risk, 58% possessed some concerns and 21% had low risk.Summary: Although evidence has shown that a number of IO modalities may improve survivorship among AYA cancer survivors, more rigorous study designs are needed in order for these modalities to be routinely recommended for use in clinical practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"36 4","pages":"211-222"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141260441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new comprehensive and stratified concept for supportive care in cancer patients. 癌症患者支持性护理的综合分层新概念。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-12 DOI: 10.1097/CCO.0000000000001039

Jean Klastersky, Isabelle Libert, Yves Libert, Marie-Aline Echterbille

{"title":"A new comprehensive and stratified concept for supportive care in cancer patients.","authors":"Jean Klastersky, Isabelle Libert, Yves Libert, Marie-Aline Echterbille","doi":"10.1097/CCO.0000000000001039","DOIUrl":"10.1097/CCO.0000000000001039","url":null,"abstract":"Purpose of review: Supportive care in oncology has evolved alongside effective anticancer treatments since the 1960s, beginning with the advent of chemotherapy for acute leukemia. It was initially focused on managing treatment-induced complications, and expanded to address broader aspects of patient well being; the scope of supportive care needs to be periodically re-assessed.Recent findings: Early palliative care interventions, and more recently advance care planning emerged as vital components, improving patient outcomes and quality of life. Despite barriers, such as prognostic uncertainty, these approaches have demonstrated significant benefits for patients with advanced disease. Additionally, the management of cancer survivors requires ongoing medical surveillance and psycho-social support. In the last years, integrative medicine has also emerged as a complementary approach to address survivors' holistic needs.Summary: A proposed stratified model of supportive care emphasizes interventions based on patients' prognosis, with interdisciplinary collaboration ensuring comprehensive care across all stages of the cancer journey. This model provides a framework for the development of integrated supportive care units.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"206-210"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Active surveillance and emerging medical treatment options for desmoid: when and for whom? 脱屑病的主动监测和新出现的药物治疗方案：何时治疗，对谁治疗？

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-07 DOI: 10.1097/CCO.0000000000001049

Sylvie Bonvalot, Aisha Miah, Bernd Kasper

{"title":"Active surveillance and emerging medical treatment options for desmoid: when and for whom?","authors":"Sylvie Bonvalot, Aisha Miah, Bernd Kasper","doi":"10.1097/CCO.0000000000001049","DOIUrl":"10.1097/CCO.0000000000001049","url":null,"abstract":"Purpose of review: This article discusses the evolving approaches to desmoid tumors management, shedding light on recent developments.Recent findings: Active surveillance has become the primary approach for managing primary peripheral desmoid tumors. This strategy was initially based on evidence from retrospective studies. Roughly 50% of cases managed with active surveillance show spontaneous stabilization or regression. Recent prospective trials conducted in Italy, The Netherlands, and France (2022-2023) confirm the efficacy of active surveillance, revealing 3-year progression-free survival rates ranging from 53.4 to 58%. For the patients under active surveillance, decisions regarding treatment are based on significant tumor growth or progressive symptoms. Moreover, three contemporary randomized trials investigated medical treatments for progressive or recurrent desmoid tumors. Sorafenib, pazopanib, and nirogacestat demonstrated clinical activity, as evidenced by favorable progression-free survival and objective response rates.Summary: Active surveillance has solidified its position as the primary management approach for desmoid tumors, validated by three robust prospective studies. Three recent randomized trials explored medical treatment for progressive or recurrent desmoid tumors, revealing promising clinical activities.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"263-268"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies. 胃肠道恶性肿瘤中成纤维细胞生长因子受体导向疗法的最新进展和发展趋势。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-07 DOI: 10.1097/CCO.0000000000001047

Charlotte Hanssens, Oumnia Mouna, Michel Meyers, Alain Hendlisz

{"title":"State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies.","authors":"Charlotte Hanssens, Oumnia Mouna, Michel Meyers, Alain Hendlisz","doi":"10.1097/CCO.0000000000001047","DOIUrl":"10.1097/CCO.0000000000001047","url":null,"abstract":"Purpose of review: This review is timely and relevant due to the increasing recognition of the significance of the fibroblast growth factor receptor (FGFR) family in cancer biology. Understanding the role of FGFRs and their dysregulation in various cancers is crucial for developing targeted therapies and improving patient outcomes.Recent findings: The review highlights the importance of the FGFR family in cellular processes such as growth, proliferation, and survival. It discusses how abnormalities in FGFR2, including overexpression, gene amplification, and other genetic alterations, contribute to cancer progression, particularly in gastro-intestinal cancers. The paper also emphasizes the promising results of FGFR-targeted therapies, especially tyrosine kinase inhibitors, in certain cancers such as cholangiocarcinoma and oesophagogastric cancers.Summary: The findings underscore the potential of FGFR-targeted therapies in treating cancers with FGFR dysregulation. However, the review also addresses the challenges associated with these therapies, including toxicities and mechanisms of resistance. Understanding these complexities is essential for optimizing the efficacy of FGFR-targeted treatments and improving patient outcomes in clinical practice and research efforts.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"320-325"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies. 胃肠道恶性肿瘤的克劳丁定向疗法的最新进展和未来趋势。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-04-23 DOI: 10.1097/CCO.0000000000001041

Jane E Rogers, Jaffer A Ajani

{"title":"State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.","authors":"Jane E Rogers, Jaffer A Ajani","doi":"10.1097/CCO.0000000000001041","DOIUrl":"10.1097/CCO.0000000000001041","url":null,"abstract":"Purpose of review: Claudins, components of tight cell junctions in epithelial and endothelial cells, have emerged as a therapeutic target in gastrointestinal (GI) malignancies, particularly claudin 18.2 (CLDN18.2).Recent findings: Zolbetuximab, a chimeric anti-CLDN18.2 monoclonal antibody (mAb), is currently under FDA review and may emerge as the first claudin targeted therapy approved. Phase 3 trials show that zolbetuximab in combination with front-line fluoropyrimidine plus oxaliplatin improves survival in advanced CLDN18.2 positive (≥75% of tumor cells) gastric adenocarcinoma (GAC) patients. Many other therapies (mAbs; CART; bispecific; ADCs) are under investigation.Summary: CLDN18.2 will be an important target in GAC. Early understanding of how to target CLDN18.2 based on the level of expression (high, moderate, low) will be the key to success in this area. Studying these as separate entities should be considered. Resistance patterns, loss of CLDN18.2 expression, role in the refractory setting, and if any role in localized disease are questions that remain. Other targets for claudin that target claudin six and four are under investigation. Their role in GI malignancies will soon be further clarified.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"308-312"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies. 胃肠道恶性肿瘤中 HER2 靶向疗法的最新进展和未来趋势。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-01 DOI: 10.1097/CCO.0000000000001043

Jaeyop Lee, Geoffrey Ku

{"title":"State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies.","authors":"Jaeyop Lee, Geoffrey Ku","doi":"10.1097/CCO.0000000000001043","DOIUrl":"10.1097/CCO.0000000000001043","url":null,"abstract":"Purpose of review: This review critically evaluates the evolution and current status of human epidermal growth factor receptor 2 (HER2)-directed therapies in upper gastrointestinal (GI) malignancies, a timely and relevant inquiry given the dynamic shifts in therapeutic strategies over the past decade. Initial enthusiasm following the Trastuzumab for Gastric Cancer (ToGA) study's demonstration of trastuzumab's efficacy, however, encountered hurdles due to subsequent trials showing limited progress, underscoring the necessity for a reevaluation of therapeutic approaches and the exploration of novel agents.Recent findings: The review highlights significant breakthroughs in the form of immune checkpoint inhibitors and innovative therapeutic technologies, which have redefined treatment paradigms and shown promising efficacy in HER2-positive cases. Emerging treatments such as trastuzumab deruxtecan (T-DXd), zanidatamab and evorpacept further illustrate the ongoing efforts to leverage unique mechanisms of action for improved HER2-positive antitumor activity.Summary: The advancements in HER2-directed therapies underscore a pivotal era in the management of upper GI malignancies. These developments not only reflect the profound impact of integrating novel therapeutic combinations but also highlight the critical role of ongoing research in overcoming resistance mechanisms and tailoring treatment to individual disease profiles.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"326-331"},"PeriodicalIF":2.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in testing for human papillomavirus -mediated head and neck cancer. 人类乳头瘤病毒介导的头颈癌检测进展。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-03-19 DOI: 10.1097/CCO.0000000000001029

Hisham Mehanna, Laia Alemany, Christian von Buchwald

{"title":"Advances in testing for human papillomavirus -mediated head and neck cancer.","authors":"Hisham Mehanna, Laia Alemany, Christian von Buchwald","doi":"10.1097/CCO.0000000000001029","DOIUrl":"10.1097/CCO.0000000000001029","url":null,"abstract":"Purpose of review: New evidence has recently emerged regarding the utility and benefits of dual p16 INKa (p16) and Human papillomavirus (HPV) status testing when determining the diagnosis and prognosis of patients with oropharyngeal cancer.Recent findings: HPV RNA polymerase chain reaction (PCR) is the most accurate diagnostic test. The other assays (HPV DNA PCR, HPV DNA/RNA in-situ hybridization (ISH) and p16) applied to formalin fixed tumour tissue have varying but high sensitivities and specificities. Dual p16 and HPV testing identifies discordant (p16+/HPV- or p16-/HPV+) results in 9.2% of cases, who have significantly poorer prognoses than p16+/HPV+, particularly in smokers. The proportion of discordant cases varies by region, and appears to be highest in regions with lowest attributable (p16+/HPV+) fractions. Dual testing improves prognostication for oropharyngeal cancer cases by identifying discordant cases and improving the prognostic power of the Tumour Node Metastasis (TNM) classification, especially in regions with high discordant rates.Summary: Dual testing is essential when considering patients for clinical trials of treatment de-escalation, and may be important when counselling patients on prognosis, especially in regions with high discordant rates and in smokers.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"143-146"},"PeriodicalIF":2.8,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140173997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular and nutritional markers in head and neck cancer. 头颈癌的分子和营养标记。

IF 3.4 4区医学

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI: 10.1097/CCO.0000000000001034

Gerard Milano, Jocelyn Gal, René-Jean Bensadoun

{"title":"Molecular and nutritional markers in head and neck cancer.","authors":"Gerard Milano, Jocelyn Gal, René-Jean Bensadoun","doi":"10.1097/CCO.0000000000001034","DOIUrl":"10.1097/CCO.0000000000001034","url":null,"abstract":"Purpose of review: There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN.Recent findings: Human papilloma virus (HPV) positivity translated by the presence of the protein indicator p16 is synonymous of favorable prognosis SCCHN. However, there is some disparity for disease evolution among p16 positive SCCHN. A lack of correlation between immunohistochemistry (IHC) and precise quantification of active epidermal growth factor receptors (EGFRs) may explain the absence of link between EGFR expression performed by IHC and response to EGFR targeting therapies reported in SCCHN. Circulating tumor cells (CTCs) have the property to share the main somatic mutations and genetic rearrangements with the primary tumors. A particular potential interest lies on the possibility to predict patient outcome based on a single-CTC analysis.Summary: This short review indicates that key biological marker reflecting disease outcome is not yet emerging for a clinical use in SCCHN. Hopes can be put into the so-called liquid biopsies incorporating circulating tumor cells and circulating tumor DNA.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"123-127"},"PeriodicalIF":3.4,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140027621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0